drugset / Trial / NCT07376200

Single-ascending Dose Study of HEC-151 Injection

NCT07376200

Phase 1 Recruiting 81 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

Timeline

Start
2026-02-24
Primary completion
2026-09-05
Completion
2026-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC-151 Unknown Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.